Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosing - PubMed
7 hours ago
- #tyrosine kinase inhibitors
- #chronic myeloid leukemia
- #adverse events
- Targeted therapies, especially tyrosine kinase inhibitors (TKIs), have improved life expectancy for chronic phase chronic myeloid leukemia (CML) patients.
- Long-term therapy is often necessary, and discontinuation may lead to CML recurrence in some patients.
- TKIs, including ATP binding site and allosteric inhibitors, can cause treatment-emergent adverse events (TEAEs) affecting quality of life.
- Switching therapies may not eliminate side effects, as new ones can emerge.
- This review discusses the incidence of hematologic and non-hematologic TEAEs, offers management guidance, and explores the effects of dose reduction on efficacy and tolerability.